Are we getting closer to prevention and treatment of corneal neovascularization?

Clinical and Experimental Ophthalmology

Volumn 35, Issue 8, 2007, Pages 689-690

  Chévez Barrios, Patricia ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 3;

ANTIANGIOGENIC ACTIVITY; CELL PROLIFERATION; CHILD CARE; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; ENDOTHELIUM CELL; EXTENDED WEAR CONTACT LENS; EYE INFECTION; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PREVALENCE; REFRACTION ERROR; SINGLE DRUG DOSE; SOFT CONTACT LENS; UPREGULATION; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CORNEAL NEOVASCULARIZATION; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36049049227     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2007.01616.x     Document Type: Editorial

References (8)

1. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 2007; 35: 745-8
2. Manzano RP, Peyman GA, Khan P et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007; 91: 804-7.
3. Bock F, Onderka J, Dietrich T et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545-52.
4. Denekamp J. Vasculature as a target for tumor therapy. In: Hammerson F, Hudlicka O, eds. Progress in Applied Microcirculation. Basel: Karger, 1984; 28.
5. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
6. Colby KA, Adamis AP. Prevalence of corneal neovascularization in a general eye service population (Abstract). Invest Ophthalmol Vis Sci 1996; 37: S593.
7. Lee P, Wang CC, Adamis AP. Ocular neovascularization: An epidemiologic review. Surv Ophthalmol 1998; 43: 245-69.
8. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-35.